AllSci News
ASCO: 858 Therapeutics' posts 57% response rate for PARG inhibitor in BRCA-mutated ovarian and breast cancer
858 Therapeutics reported a 57% objective response rate for ETX-19477 in a small Phase 2-eligible subset of patients with BRCA-mutated platinum-resistant...
Whitehawk Therapeutics licenses Hangzhou DAC's CPT113 linker-payload for up to five ADC programs
Whitehawk Therapeutics (Nasdaq: WHWK) has entered an option agreement with China's Hangzhou DAC Biotech to access the CPT113 linker-payload technology...
ASCO: Innovent, Takeda's PD-1/IL-2 bispecific shows 86.4% response rate in early trial for NSCLC
Innovent Biologics (HKEX: 01801), the Suzhou-based biopharmaceutical company, reported preliminary proof-of-concept data from the IBI363 NSCLC trial at the...
Oorja Bio emerges from stealth mode with USD 30m Series A to advance pulmonary fibrosis peptide ORJ-001
Oorja Bio, a Houston-based clinical-stage biopharmaceutical company, has launched with USD 30 million in Series A financing from founding investor Westlake...
MaaT Pharma receives negative trend opinion from European Medicines Agency for Xervyteg
MaaT Pharma (Euronext: MAAT), based in Lyon, France, received a “negative trend” opinion from the European Medicines Agency’s Committee for Medicinal Products…
Bayer’s finerenone mineralocorticoid receptor antagonist gains FDA Priority Review for type 1 diabetes
Bayer announced receipt of US FDA Priority Review status for its supplemental New Drug Application (sNDA) relating to Kerendia (finerenone), a non-steroidal…
Scribe's epigenetic silencer targeting PCSK9 for single-dose LDL reduction enters first human trial
Scribe Therapeutics, an Alameda, California-based biotechnology company, has received clearance from the Australian Therapeutic Goods Administration (TGA)...
Lupeng's rocbrutinib challenges Eli Lilly's Jaypirca in Phase III relapsed refractory CLL trial
Lupeng Pharmaceutical Ltd has enrolled the first patient in the ROCKET-CLL trial, a global Phase III study pitting rocbrutinib (LP-168) directly against Eli...
BioMarin's vosoritide meets primary endpoint in Phase III hypochondroplasia trial
BioMarin Pharmaceutical (Nasdaq: BMRN) reported that vosoritide (Voxzogo) met its primary endpoint in the Phase III CANOPY-HCH-3 study in children with...
Gilead finalizes up to USD 5b acquisition of Tubulis' ADC platform
Gilead Sciences (Nasdaq: GILD) has completed its acquisition of Tubulis GmbH, a clinical-stage biotechnology company based in Munich, Germany, adding a...
Kelun-Biotech's sacituzumab tirumotecan meets primary endpoint in Phase III advanced triple-negative breast cancer trial
Sichuan Kelun-Biotech Biopharmaceutical Co. (HKEx: 6990.HK) announced that its TROP2-directed antibody-drug conjugate sacituzumab tirumotecan met the...
Immix Bio's BCMA CAR-T achieves 95% complete response rate in Phase II AL amyloidosis trial
Immix Biopharma (Nasdaq: IMMX) reported a 95% complete response rate in an interim update from its AL amyloidosis clinical trial, with 19 of 20 evaluable...
Junshi, Remegen pick up China nod for toripalimab plus disitamab vedotin in HER2+ urothelial carcinoma
Shanghai Junshi Biosciences (HKEX: 1877; SSE: 688180) has received approval from China’s National Medical Products Administration (NMPA) for Tuoyi (toripalimab) in combination…
NMPA approves HutchMed and Innovent’s Elunate and Tyvyt combination for renal cell carcinoma
HutchMed (China) Limited (Nasdaq/AIM: HCM; HKEX: 13) and Innovent Biologics (HKEX: 1801) jointly announced that China’s National Medical Products Administration (NMPA) has…
Eli Lilly's retatrutide achieves 'surgery-like' 28.3% weight loss in Phase III obesity trial
Eli Lilly (NYSE: LLY) reported that retatrutide, its investigational GIP, GLP-1, and glucagon triple hormone receptor agonist, produced a mean body weight...
The AllSci Brief
Free, systematic R&D and deal news. Daily.